{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:50:18Z","timestamp":1791323418355,"version":"4.3.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sirtex Medical Europe GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the prognostic value of the aspartate aminotransferase-to-platelet ratio index (APRI) for overall survival (OS) after transarterial radioembolization (TARE) in patients with intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) from the prospective study CIRT (CIRSE study on SIR-Spheres Therapy).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Adult patients treated with TARE Y-90 were included. Baseline, laboratory, treatment, and follow-up data were collected prospectively. Receiver operating characteristic analysis was used to determine optimal APRI cut-offs. OS from the date of TARE was analysed using Kaplan\u2013Meier. Propensity score matching and multivariable Cox regression analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      103 ICC and 377 HCC patients were analysed. Most patients had ECOG 0 (58.3%\/61.3%) or 1 (31.1%\/31.8%) in the ICC and HCC groups, respectively. Median APRI was 0.5 (IQR: 0.3\u20130.8) in ICC and 0.8 (IQR: 0.4\u20131.4) in HCC. Higher APRI values were associated with significantly shorter OS in both cohorts using different thresholds (ICC: APRI\u2009&gt;\u20090.4; HCC: APRI\u2009&gt;\u20090.7). These associations remained significant after propensity score matching and multivariable analysis. APRI was an independent prognostic factor for OS in both ICC (95% CI 1.25\u20135.23;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010) and HCC (95% CI 1.04\u20132.06;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028). The identified APRI cut-offs were associated with survival differences when body surface area (BSA) and modified BSA dosimetry were used, but not with partition model dosimetry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>APRI may be a promising, easily accessible prognostic biomarker for OS after TARE in ICC and HCC patients. Its prognostic value may be influenced by tumour type and counteracted by dosimetry method, supporting further investigation on this topic.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      NCT02305459\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00270-026-04483-7","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:43:12Z","timestamp":1779900192000},"page":"2064-2071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aspartate Aminotransferase to Platelet Index (APRI) as a Prognostic Factor for Overall Survival After TARE Y90 Resin Microspheres in Primary Liver Cancer Patients: Results from the European, Prospective Observational Study CIRT"],"prefix":"10.1007","volume":"49","author":[{"given":"Niklaus","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7683-1322","authenticated-orcid":false,"given":"Maria","family":"Urdaniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Helmberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"4483_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2021","unstructured":"Vogel A, Martinelli E, Cervantes A, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32:801\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014.","journal-title":"Ann Oncol"},{"key":"4483_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"D Alvaro","year":"2023","unstructured":"Alvaro D, Gores GJ, Walicki J, et al. EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79:181\u2013208. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.010.","journal-title":"J Hepatol"},{"key":"4483_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","volume":"36","author":"A Vogel","year":"2025","unstructured":"Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:491\u2013506. https:\/\/doi.org\/10.1016\/j.annonc.2025.02.006.","journal-title":"Ann Oncol"},{"key":"4483_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2021.05.032","volume":"154","author":"H Pereira","year":"2021","unstructured":"Pereira H, Bouattour M, Dioguardi Burgio M, et al. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). Eur J Cancer. 2021;154:46\u201356. https:\/\/doi.org\/10.1016\/j.ejca.2021.05.032.","journal-title":"Eur J Cancer"},{"key":"4483_CR5","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s12325-022-02099-0","volume":"39","author":"I Agirrezabal","year":"2022","unstructured":"Agirrezabal I, Brennan VK, Colaone F, et al. Transarterial radioembolization versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: a matching-adjusted indirect comparison of time to deterioration in quality of life. Adv Ther. 2022;39:2035\u201351. https:\/\/doi.org\/10.1007\/s12325-022-02099-0.","journal-title":"Adv Ther"},{"key":"4483_CR6","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","volume":"11","author":"R Salem","year":"2013","unstructured":"Salem R, Gilbertsen M, Butt Z, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11:1358-1365.e1. https:\/\/doi.org\/10.1016\/j.cgh.2013.04.028.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4483_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518\u201326. https:\/\/doi.org\/10.1053\/jhep.2003.50346.","journal-title":"Hepatology"},{"key":"4483_CR8","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.2147\/CMAR.S174095","volume":"10","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Zhang X. Prognostic value of aspartate aminotransferase to platelet ratio index as a noninvasive biomarker in patients with hepatocellular carcinoma: a meta-analysis. Cancer Manag Res. 2018;10:3023\u201332. https:\/\/doi.org\/10.2147\/CMAR.S174095.","journal-title":"Cancer Manag Res"},{"key":"4483_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/00365513.2014.981759","volume":"75","author":"Q Pang","year":"2015","unstructured":"Pang Q, Zhang JY, Xu XS, et al. The prognostic values of 12 cirrhosis-relative noninvasive models in patients with hepatocellular carcinoma. Scand J Clin Lab Invest. 2015;75:73\u201384. https:\/\/doi.org\/10.3109\/00365513.2014.981759.","journal-title":"Scand J Clin Lab Invest"},{"key":"4483_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.crad.2017.09.004","volume":"73","author":"T Tang","year":"2018","unstructured":"Tang T, Qiu JL, Li GW, et al. Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients. Clin Radiol. 2018;73:259\u201365. https:\/\/doi.org\/10.1016\/j.crad.2017.09.004.","journal-title":"Clin Radiol"},{"key":"4483_CR11","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.31557\/APJCP.2022.23.11.3939","volume":"23","author":"N Inmutto","year":"2022","unstructured":"Inmutto N, Nimitrungtawee N, Srisuwan T, et al. Investigating up-to-seven criteria and APRI (AST platelet ratio) as prognostic factors in intermediate-stage hepatocellular carcinoma patients who received transarterial chemoembolization. Asian Pac J Cancer Prev. 2022;23:3939\u201346. https:\/\/doi.org\/10.31557\/APJCP.2022.23.11.3939.","journal-title":"Asian Pac J Cancer Prev"},{"key":"4483_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.61904","author":"MP del Bayona Molano","year":"2024","unstructured":"del Bayona Molano MP, Kolber M, Barrera JV, et al. Prognostic value of liver biomarkers in hepatocellular carcinoma patients undergoing yttrium 90 transarterial radioembolization (TARE): a retrospective pilot study. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.61904.","journal-title":"Cureus"},{"key":"4483_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jhep.2021.11.018","volume":"3","author":"M Reig","year":"2025","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2025 update. J Hepatol. 2025;3:631\u201354. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"4483_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.clcc.2022.09.002","volume":"21","author":"N Schaefer","year":"2022","unstructured":"Schaefer N, Gr\u00f6zinger G, Pech M, et al. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022;21:285\u201396. https:\/\/doi.org\/10.1016\/j.clcc.2022.09.002.","journal-title":"Clin Colorectal Cancer"},{"key":"4483_CR15","doi-asserted-by":"publisher","DOI":"10.2196\/16296","author":"T Helmberger","year":"2020","unstructured":"Helmberger T, Arnold D, Bilbao JI, et al. Clinical application of radioembolization in hepatic malignancies: protocol for a prospective multicenter observational study. J Med Internet Res. 2020. https:\/\/doi.org\/10.2196\/16296.","journal-title":"J Med Internet Res"},{"key":"4483_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"ZH Lin","year":"2011","unstructured":"Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726\u201336. https:\/\/doi.org\/10.1002\/hep.24105.","journal-title":"Hepatology"},{"key":"4483_CR17","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(17)30683-6.","journal-title":"Lancet Oncol"},{"key":"4483_CR18","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913\u201321. https:\/\/doi.org\/10.1200\/JCO.2017.76.0892.","journal-title":"J Clin Oncol"},{"key":"4483_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","volume":"296","author":"AL Hermann","year":"2020","unstructured":"Hermann AL, Dieudonn\u00e9 A, Ronot M, et al. Relationship of tumor radiation\u2013absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study. Radiology. 2020;296:673\u201384. https:\/\/doi.org\/10.1148\/radiol.2020191606.","journal-title":"Radiology"},{"key":"4483_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-026-04483-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:00:21Z","timestamp":1791320421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-026-04483-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4483"],"URL":"https:\/\/doi.org\/10.1007\/s00270-026-04483-7","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dirk Arnold received consulting fees and honoraria for presentations and lectures and travel support from Boston Scientific and Terumo, MSD, BMS, AstraZeneca, Roche, Servier, Sanofi and Merck Serono. He is on the guidelines committee of the European Society for Medical Oncology, and supported oncopolicy manuscripts for the European Cancer Organisation. Thomas Helmberger, Niklaus Schaefer, Milan Geyer, Maria Urdaniz and Niels de Jong had nothing to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the national ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study has been approved by the applicable ethics committees.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants signed an informed consent form.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}